Logo
O

Obsidian Therapeutics

118 employees

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients. Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need. Located in the heart of Cambridge with a new laboratory facility in Bedford, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.

Investor insights

Funding rounds participated in

$161M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2015

Funding rounds raised

Total raised

$161M

from 2 investors over 1 rounds

O

Obsidian Therapeutics raised $161M on May 3, 2024

Investors: Wellington Management and + 15 Other investors

FAQ